Professor Ghosn's passion for advancing oncology care is evident in his groundbreaking research, particularly in the Middle East and Arab world, where he has over 300 publications. His extensive publication record includes pioneering work in breast cancer, urological oncology, and gastrointestinal cancer.

Key real world evidence (RWE) studies performed:

• The TRIPOLI Study: Presented at the San Antonio Breast Cancer Congress in 2023, this study shed new light on triple negative breast cancer and immunotherapy treatment outcomes in the Arab world (Submitted for publication).
• OSSMAR Study: A landmark 10-year research project on renal cancer, providing unprecedented insights into treatment efficacy in Middle Eastern patients.
• OPERA Study: Encompassing over 200 patients from various Arab countries, this ongoing prospective study (set to conclude in January 2025) is furthering our understanding of renal cancer treatment in diverse populations.

Precision Medicine

Professor Ghosn's commitment to precision medicine is exemplified by his pioneering work:

• 2016 NGS Study: One of the first large-scale Next Generation Sequencing studies in the region. This study, published in the Bulletin du cancer, involved over 180 patients and catalyzed the adoption of precision medicine in clinical practice, nearly a decade ahead of its widespread implementation.

Whole-Person Care

• Pioneering Anti-Aging Through Stem Cell Therapy (2024): A groundbreaking review exploring stem cell therapy's potential in anti-aging medicine, demonstrating the role of cellular therapy in tissue regeneration and healthy aging.
• Patient Supplement Usage Study (2024): Evaluates the importance of integrated cancer care, highlighting that supplements without proper multidisciplinary medical supervision may not optimize patient outcomes, which supports the need for comprehensive team-based treatment approaches.